Sign in

    Neogen Corp (NEOG)

    You might also like

    Neogen Corporation develops, manufactures, and markets a diverse range of products and services dedicated to ensuring food and animal safety. The company provides diagnostic test kits, veterinary instruments, pharmaceuticals, and biosecurity products to detect harmful substances, maintain sanitation, and promote animal health. Neogen operates globally, serving food producers, processors, veterinarians, and livestock producers with innovative solutions.

    1. Food Safety - Offers diagnostic test kits and related products to detect foodborne pathogens, allergens, natural toxins, and sanitation levels. Includes genomics-based diagnostic technology and software systems for data analysis and storage.

      • Sub-products: Culture media, DNA detection products, and immunoassay kits.
    2. Animal Safety - Provides veterinary instruments, pharmaceuticals, vaccines, parasiticides, and diagnostic products for animal health. Includes biosecurity products such as rodent control, insect control, disinfectants, and genomics testing services.

      • Sub-products: Drug detection products for animals and workplace/human forensic markets.
    NamePositionStart DateShort Bio
    John E. AdentPresident & Chief Executive OfficerJuly 17, 2017Joined Neogen as CEO on July 17, 2017 and became President on September 22, 2017. Previously CEO of Animal Health International and Patterson Companies' Animal Health Division.
    Douglas E. JonesChief Operating Officer (Retiring February 28, 2025)August 17, 2020Joined Neogen as Chief Commercial Officer on August 17, 2020, became COO in 2022, and will retire on February 28, 2025. Formerly President of Patterson Companies' Companion Animal Division.
    David H. NaemuraChief Financial Officer & Chief Operating Officer (Effective January 1, 2025)November 2022Joined Neogen as CFO in November 2022 and will assume COO responsibilities on January 1, 2025. Previously CFO at Vontier Corporation and Gates Industrial Corporation.
    Amy M. RocklinChief Legal & Compliance Officer, Corporate SecretaryMarch 2021Joined Neogen in March 2021 as VP, General Counsel & Corporate Secretary, and became Chief Legal & Compliance Officer in 2022. Oversees legal, compliance, regulatory, and ESG functions.
    Thierry BernardUpcoming Board Member (Effective November 1, 2024)November 1, 2024Will join Neogen's Board as an independent director on November 1, 2024. Currently CEO of QIAGEN N.V. and previously held senior roles at bioMérieux SA.
    1. Given the significant impairment charge related to the 3M Food Safety acquisition, despite your confidence in its post-integration prospects, can you elaborate on the specific end market and integration complexities that led to this impairment and how you plan to address them moving forward?

    2. With the proactive restructuring of your genomics business resulting in intentional revenue attrition, how do you foresee this impacting your overall margins and long-term growth, especially as you focus more on your differentiated cattle genomics offering?

    3. The ramp-up of sample collection production has taken longer than anticipated, leading to revenue loss and inability to fully meet demand; what specific challenges have you faced, and what measures are you implementing to reach full capacity by the end of the third quarter?

    4. Elevated shipping and distribution costs have negatively impacted your margins, and you've initiated actions to improve efficiency; why were these inefficiencies not addressed earlier, and can you provide more details on the operational changes being made to reduce these costs?

    5. You are exploring strategic alternatives for a significant portion of your Animal Safety segment, targeting around half of its revenue; what criteria are guiding these decisions, and how will these potential divestitures enhance shareholder value and align with your focus on the food safety market?

    Program DetailsProgram 1
    Approval DateOctober 2018
    End Date/DurationNo expiration date
    Total Additional Amount6,000,000 shares
    Remaining Authorization5,900,000 shares (as of 2025-01-22)
    DetailsNo shares repurchased as of the latest updates